Paper Details

  1. Home
  2. Paper Details

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

Author: BosGerard M, CoenenJules Llm, CroockewitSandra, DelforgeMichel, JieKon-Siong G, KerstenMarie José, KleinSaskia K, LevinMark-David, LokhorstHenk M, MinnemaMonique C, SchaafsmaRon, SinnigeHarm, SonneveldPieter, VellengaEdo, YpmaPaula, ZweegmanSonja, de WaalEsther G, de WeerdtOkke, van de DonkNiels Wcj, van der HoltBronno, von dem BornePeter A

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This follow-up analysis of the HOVON-50 phase 3 trial investigated the long-term effects of thalidomide in induction and maintenance therapy for patients with newly diagnosed multiple myeloma. The study found that thalidomide-containing regimens were associated with improved event-free survival compared to regimens containing classical cytotoxic drugs after a median follow-up of 52 months.
Paper Details　
Original Abstract of the Article :
In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and maintenance regimens (in conjunction with high-dose melphalan and autologous stem cell transplantation [auto-SCT]) after a median of 52 months...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3026(18)30149-2

データ提供：米国国立医学図書館（NLM）

Thalidomide's Long-Term Benefits in Multiple Myeloma

The world of [oncology] is constantly evolving, and [multiple myeloma] research is no exception. This study explores the long-term effects of [thalidomide] in [induction and maintenance therapy] for [multiple myeloma] patients. This is a [phase 3, randomized controlled trial] that provides valuable insights into the long-term efficacy and safety of this drug.

The study found [that thalidomide treatment improves event-free survival in patients with multiple myeloma]. This is a significant finding, as it suggests that [thalidomide] can play a crucial role in the long-term management of this disease.

A New Oasis for Multiple Myeloma Patients

This research offers hope to [multiple myeloma] patients by demonstrating the long-term benefits of [thalidomide] treatment. It's a testament to the progress in [oncology] and highlights the potential of [thalidomide] to improve patient outcomes.

The Power of Persistence

While [thalidomide] can be a valuable tool in the battle against [multiple myeloma], it's important to remember that this disease can be complex and individual responses to treatment can vary. As with any medical treatment, it's crucial to consult with a medical professional for personalized care and advice.

Dr. Camel's Conclusion

This study is like a refreshing oasis in the vast desert of [multiple myeloma] research. It’s encouraging to see that [thalidomide] can provide long-term benefits to patients, which is a crucial step towards improving their lives. We're on the right path to understanding and treating this complex disease.

Date :
  1. Date Completed 2018-11-22
  2. Date Revised 2018-11-22
Further Info :

Pubmed ID

30290905

DOI: Digital Object Identifier

10.1016/S2352-3026(18)30149-2

Related Literature

Article Analysis
・Side Effects of lenalidomide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.